Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 4, 2014, Pages 759-770

  Freiwald, Matthias ^a   Schmid, Ulrike ^a   Fleury, Angele ^a   Wind, Sven ^a   Stopfer, Peter ^a   Staab, Alexander ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Afatinib; ErbB family blocker; Human; NONMEM; Population pharmacokinetics; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BREAST METASTASIS; CANCER PATIENT; CAUCASIAN; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE SCORE; FEMALE; FOOD INTAKE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SMOKING; SOLID TUMOR; STEADY STATE;

ABSORPTION; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84898057419     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2403-2     Document Type: Article

References (23)

1. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342-350
2. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133(3):1057-1065
3. Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Greve J, Neven P, Dirix L, Jonat W, Beckmann MW, Schutte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N (2012) A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 134(3):1149-1159
4. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13(5):528-538
5. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA (2012) Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 13(5):539-548
6. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327-3334
7. Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N (2012) Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 69(4):891-899
8. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31(27):3335-3341
9. Cohen EEW, Fayette J, Cupissol D, Del Campo JM, Clement PM, Tourani JM, Degardin M, Zhang W, Ehrnrooth E, Seiwert TY (2012) A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data (abstract PP101). Eur Arch Otorhinolaryngol 269(4):1374
10. Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P (2013) Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 52(12):1101-1109
11. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28(25):3965-3972
12. Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, Ebner T (2012) Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 69(4):1051-1061
13. Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, Hocke J, Gansser D, Stopfer P (2014) Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig Jan 8 (Epub ahead of print)
14. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98(1):80-85
15. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85-94
16. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241-257
17. Food and Drug Administration Center for Drug Evaluation and Research (2013). Afatinib clinical pharmacology NDA review, Nov 2013. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/ 201292Orig1s000ClinPharmR.pdf. Accessed 21 Nov 2013
18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41
19. Yardley DA (2009) Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist 14(5):448-455
20. Bristol-Myers Squibb (2011). Ixempra kit (ixabepilone) for injection, for intravenous infusion only. Prescribing information, revised: 10/2011. http://packageinserts.bms.com/pi/pi-ixempra.pdf. Accessed 21 Nov 2013
21. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143-151
22. Food and Drug Administration (2010). Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. March 2010. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf. Accessed 21 Nov 2013
23. Schnell D, Buschke S, Fuchs H, Göldner R-G, Uttenreuther-Fischer M, Stopfer P, Wind S, Halabi A, Koenen R (2012) Phase I study to compare safety and pharmacokinetics of afatinib, an oral irreversible ErbB family blocker, in non-cancer subjects with hepatic impairment to matched healthy subjects (abstract 468P). Ann Oncol 23(Suppl 9):162